Roche's Susvimo gains EC approval: a refillable ranibizumab implant for nAMD that cuts treatment frequency to as few as two injections yearly. Shifts the economics of chronic eye disease management.
Roche wins EC approval for Susvimo refillable eye implant in nAMD
The European Commission has approved Roche's Susvimo, a continuous-delivery ranibizumab implant requiring as few as two treatments per year for neovascular AMD.
biotech.disruptsmedia.com
September 23, 2026 at 2:45 PM
Roche's Susvimo gains EC approval: a refillable ranibizumab implant for nAMD that cuts treatment frequency to as few as two injections yearly. Shifts the economics of chronic eye disease management.
EC Approves $ROP Roche’s Susvimo For Eye Disease NAMD
- Phase III Archway Study Shows Susvimo Maintains Vision Equivalent To Monthly Injections
- Phase III Archway Study Shows Susvimo Maintains Vision Equivalent To Monthly Injections
September 21, 2026 at 3:52 PM
EC Approves $ROP Roche’s Susvimo For Eye Disease NAMD
- Phase III Archway Study Shows Susvimo Maintains Vision Equivalent To Monthly Injections
- Phase III Archway Study Shows Susvimo Maintains Vision Equivalent To Monthly Injections
Roche erhält EU-Zulassung für Augenmittel Susvimo
https://www.awp.ch/sharedarticles?articleid=-1972727669
https://www.awp.ch/sharedarticles?articleid=-1972727669
September 21, 2026 at 4:27 PM
Roche erhält EU-Zulassung für Augenmittel Susvimo
https://www.awp.ch/sharedarticles?articleid=-1972727669
https://www.awp.ch/sharedarticles?articleid=-1972727669
EUROPEAN COMMISSION APPROVES ROCHE’S SUSVIMO® FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
September 21, 2026 at 3:46 PM
EUROPEAN COMMISSION APPROVES ROCHE’S SUSVIMO® FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Roche's Susvimo Receives FDA Approval for Diabetic Macular Edema, A Game Changer in Eye Health#USA#Las_Vegas#DME#Susvimo#Diabetic_Macular_Edema
Roche's Susvimo Receives FDA Approval for Diabetic Macular Edema, A Game Changer in Eye Health
Roche's Susvimo has achieved FDA approval to treat diabetic macular edema, a significant advancement in eye health for diabetics. This approval underscores the growing landscape of innovative therapies for vision-related conditions.
third-news.com
April 30, 2025 at 9:37 PM
Roche's Susvimo Receives FDA Approval for Diabetic Macular Edema, A Game Changer in Eye Health#USA#Las_Vegas#DME#Susvimo#Diabetic_Macular_Edema
Genentech’s Susvimo receives new FDA indication for diabetic retinopathy www.ophthalmologytimes.com/view/genente...
Genentech’s Susvimo receives new FDA indication for diabetic retinopathy
Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months
www.ophthalmologytimes.com
May 22, 2025 at 9:25 PM
Genentech’s Susvimo receives new FDA indication for diabetic retinopathy www.ophthalmologytimes.com/view/genente...
Saudi Aramco exported 14 million barrels of crude from Ras Tanura. The European Commission approved Roche drug Susvimo for macular degeneration. A 65-year-old man was charged in the UK for 1994 Rwanda genocide offenses. German institutes raised their 2026 growth forecast to 1.3 percent.
September 21, 2026 at 4:15 PM
Saudi Aramco exported 14 million barrels of crude from Ras Tanura. The European Commission approved Roche drug Susvimo for macular degeneration. A 65-year-old man was charged in the UK for 1994 Rwanda genocide offenses. German institutes raised their 2026 growth forecast to 1.3 percent.
EMA's CHMP recommends first oral IL-23 receptor drug for psoriasis and implant-based treatment for wet AMD
🔎 AI-assisted · sourced analysis
#Underreported #Health
🔎 AI-assisted · sourced analysis
#Underreported #Health
EMA's CHMP recommends first oral IL-23 receptor drug for psoriasis and implant-based treatment for wet AMD
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorisation for Icotyde (icotrokinra), the first oral medicine targeting the interleukin-23 receptor for moderate-to-severe plaque psoriasis, and Susvimo (ranibizumab), a refillable…
theuncovered.news
July 26, 2026 at 7:48 AM
EMA's CHMP recommends first oral IL-23 receptor drug for psoriasis and implant-based treatment for wet AMD
🔎 AI-assisted · sourced analysis
#Underreported #Health
🔎 AI-assisted · sourced analysis
#Underreported #Health
Major #FDA news: Ranibizumab injection (Susvimo; Roche) 100 mg/mL administered through a port delivery platform (PDP) became the first and only FDA-approved continuous treatment to maintain vision in patients with #diabetic macular edema.
Learn more: bit.ly/4gsyaqf
Learn more: bit.ly/4gsyaqf
Ranibizumab Injection Delivered Through Port Delivery Platform Is FDA Approved as Continuous Delivery Treatment for DME
Diabetic macular edema (DME) is the leading cause of new blindness in the US.
bit.ly
February 5, 2025 at 6:41 PM
Major #FDA news: Ranibizumab injection (Susvimo; Roche) 100 mg/mL administered through a port delivery platform (PDP) became the first and only FDA-approved continuous treatment to maintain vision in patients with #diabetic macular edema.
Learn more: bit.ly/4gsyaqf
Learn more: bit.ly/4gsyaqf
Susvimo.
Does away with the injections. Just approved in the EU.
Does she have wet or dry variant?
Does away with the injections. Just approved in the EU.
Does she have wet or dry variant?
August 12, 2026 at 9:39 PM
Susvimo.
Does away with the injections. Just approved in the EU.
Does she have wet or dry variant?
Does away with the injections. Just approved in the EU.
Does she have wet or dry variant?
EU Panel Backs First Refillable Eye Implant for AMD
zurl.co/bG0vI
zurl.co/bG0vI
EU Panel Backs First Refillable Eye Implant for AMD
Susvimo, a refillable ranibizumab implant for neovascular age-related macular degeneration, could reduce treatment burden by replacing monthly injections with 24-week refills.
zurl.co
August 5, 2026 at 3:00 PM
EU Panel Backs First Refillable Eye Implant for AMD
zurl.co/bG0vI
zurl.co/bG0vI
J&J's Icotyde, Roche's Susvimo among key CHMP nods in July decisions #$JNJ #$RHHBY #$NAMS #$ZVRA firstwordpharma.com/story/7773581
July 24, 2026 at 9:45 PM
J&J's Icotyde, Roche's Susvimo among key CHMP nods in July decisions #$JNJ #$RHHBY #$NAMS #$ZVRA firstwordpharma.com/story/7773581
Roche erhält CHMP-Empfehlung für Augenimplantat Susvimo
https://www.awp.ch/sharedarticles?articleid=-1974645898
https://www.awp.ch/sharedarticles?articleid=-1974645898
July 24, 2026 at 10:42 AM
Roche erhält CHMP-Empfehlung für Augenimplantat Susvimo
https://www.awp.ch/sharedarticles?articleid=-1974645898
https://www.awp.ch/sharedarticles?articleid=-1974645898
#Ophthalmology #BoehringerIngelheim #diabeticeyedisease #diabeticmacularoedema #DME #BI1815368 #THULITEstudy #centreinvolvedDME #VEGFtargetingdrugs #Roche #Vabysmo #faricimab #Lucentis #ranibizumab #Bayer #Regeneron #Eylea #aflibercept #Susvimo #ranibizumab
pharmaphorum.com/news/boehrin...
pharmaphorum.com/news/boehrin...
Boehringer raises hope of oral drug for diabetic eye disease
Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.
pharmaphorum.com
July 11, 2025 at 8:32 AM
I will have a story about Susvimo for treating diabetic macular edema tomorrow in the Kos Diabetes group on Daily Kos.
Genentech, a member of the Roche Group, announced the FDA approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of DME. Susvimo is now available to US retina specialists+their patients with DME. ophthalmologymanagement.com/news/2025/fd... #diabeticmacularedema #dme #retina
May 14, 2025 at 5:09 AM
I will have a story about Susvimo for treating diabetic macular edema tomorrow in the Kos Diabetes group on Daily Kos.
Roche: le Susvimo approuvé pour l'oedème maculaire diabétique
#Roche #news
https://www.awp.ch/sharedarticles?articleid=-1993195388
#Roche #news
https://www.awp.ch/sharedarticles?articleid=-1993195388
February 4, 2025 at 5:27 PM
Roche: le Susvimo approuvé pour l'oedème maculaire diabétique
#Roche #news
https://www.awp.ch/sharedarticles?articleid=-1993195388
#Roche #news
https://www.awp.ch/sharedarticles?articleid=-1993195388
Feed: "Clinical Trials Arena"
By: gullapalli on Monday, August 4, 2025
By: gullapalli on Monday, August 4, 2025
Genentech reports five-year data from trial of Susvimo for wet AMD
Roche’s Genentech has reported new five-year data from the Phase III Portal trial of Susvimo for treating wet AMD.
www.clinicaltrialsarena.com
August 4, 2025 at 5:48 PM
Feed: "Clinical Trials Arena"
By: gullapalli on Monday, August 4, 2025
By: gullapalli on Monday, August 4, 2025
Feed: "Medical News, Health News Latest, Medical News Today - Medical Dialogues |"
By: Ruchika Sharma on Monday, August 4, 2025
By: Ruchika Sharma on Monday, August 4, 2025
Roche Susvimo maintains vision over five years with two refills per year in people with nAMD
Basel: Roche has announced new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo (ranibizumab...
medicaldialogues.in
August 4, 2025 at 11:55 AM
Feed: "Medical News, Health News Latest, Medical News Today - Medical Dialogues |"
By: Ruchika Sharma on Monday, August 4, 2025
By: Ruchika Sharma on Monday, August 4, 2025